Search results
Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. Stephen R.D. Johnston1, Masakazu Toi, Joyce O'Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun-Sheng Huang, Jens Huober ...
Abstract. Background: Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-negative, node-positive, high-risk, early breast cancer.
Dec 1, 2020 · The primary end point was invasive disease-free survival (IDFS), and secondary end points included distant relapse-free survival, overall survival, and safety. Results: At a preplanned efficacy interim analysis, among 5,637 randomly assigned patients, 323 IDFS events were observed in the intent-to-treat population.
- Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Y...
- 2020
Sep 20, 2020 · eligible and randomly assigned (1:1) to standard-of-care adjuvant endocrine therapy (ET) with or without abemaciclib (150 mg twice daily for 2 years). The primary end point was invasive disease-free survival (IDFS), and secondary end points included distant relapse–free survival, overall survival, and safety.
Professor Stephen Johnston has worked for many years to understand endocrine resistance in hormone receptor positive breast cancer. He has led many trials investigating novel therapies to improve efficacy of current hormone treatments.
Sep 28, 2020 · Prof. Stephen Johnston discusses the recent phase III MonarchE trial, the data presented at the Virtual 2020 ESMO Congress, and the role of abemaciclib in the treatment of HR+, HER2-, high-risk early breast cancer.
Stephen Johnston is Professor of Breast Cancer Medicine, Consultant Medical Oncologist and Head of the Breast Unit at The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London.
